A patent from Centre National de la Recherche Scientifique (CNRS), McGill University and Sorbonne University discloses new acetylcholinesterase (AChE) inhibitors reported to be useful for the treatment of substance abuse and dependence, obsessive-compulsive disorder, anorexia nervosa, bulimia nervosa, obesity, Parkinson’s and Alzheimer’s disease.
Mutations in the GNAO1 gene are tied to neurological disorders characterized by movement abnormalities and developmental delay. GNAO1 encodes the protein guanine nucleotide-binding protein G(o) subunit α, which is highly expressed in the brain. Among the mutations, R209H results in dystonia, choreoathetosis and developmental delay without seizures.
Restoring glucose metabolism in astrocytes, which is impaired in Alzheimer’s disease (AD), has a direct effect on neurons, which replenish their fuel supply and resume synaptic activity. A group of scientists from Stanford University School of Medicine has revealed the pathway that explains where this efflux is interrupted and which molecules restore it in mouse models with amyloid and tau pathology. Their findings could help prevent the progression of this neurodegenerative disease.
Work at DE Shaw Research LLC has led to the identification of bicyclic imide compounds acting as transient receptor potential cation channel subfamily A member 1 (TRPA1) antagonists.
Eurofarma Laboratórios SA and Universidade Federal do Rio de Janeiro (UFRJ) have jointly patented new sodium channel protein type 9 subunit α (SCN9A; Nav1.7) and/or SCN10A (Nav1.8) blockers reported to be useful for the treatment of pain.
Lucy Therapeutics Inc. has disclosed new mitochondrial F1F0 ATPase hydrolase inhibitors potentially useful for the treatment of cancer, acute coronary syndrome, ischemia, neurodegeneration and Parkinson's disease.
Several recent Janssen Pharmaceutica NV patents describe new NLRP3 inflammasome inhibitors reported to be useful for the treatment of traumatic brain injury, multiple sclerosis, amyotrophic lateral sclerosis, dementia, Huntington’s, Parkinson’s, Alzheimer’s and motor neuron diseases.
Purdue Research Foundation has discovered compounds for inhibiting protein aggregation potentially useful for the treatment of wild-type transthyretin amyloidosis, type 2 diabetes, amyotrophic lateral sclerosis and more.
People with the rare inherited metabolic disorder Gaucher disease have a deficiency in the lipid-digesting glucocerebrosidase enzyme, which causes the accumulation of harmful levels of glucolipids in various organs. The enzyme has a very short half-life, which rules out enzyme replacement as an effective therapy, and as things stand, there are few treatments for this and other lysosomal storage diseases (LSDs). Now, researchers have discovered two small molecules that enhance the activity of glucocerebrosidase in cellular models of LSD, pointing to a potential new approach to treating these diseases.
Daiichi Sankyo Co. Ltd. has divulged compounds acting as NLRP3 inflammasome inhibitors reported to be useful for the treatment of inflammation, major depression, multiple sclerosis, multiple system atrophy, schizophrenia, autoimmune disease, Alzheimer’s disease and Parkinson’s disease, among others.
RSS
